HOME >> BIOLOGY >> NEWS
Don't care for broccoli? A receptor gene's variation suggests an evolutionary excuse

By testing the bitterness perceived by individuals possessing different versions of the same taste receptor, researchers have obtained new evidence supporting the idea that evolution of the receptor gene has shaped avoidance of certain vegetables that can inhibit thyroid function. The findings are reported by Mari Hakala and Paul Breslin of Monell Chemical Sciences Center in Philadelphia, Pennsylvania and appear in the September 19th issue of Current Biology, published by Cell Press.

Compounds known as glucosinolates are present in a variety of vegetables included in the human diet (especially Cruciferous vegetables), but these compounds can block the formation of organic iodine and the transport of iodine into the thyroid. Iodine is necessary for proper thyroid function, and in geographic regions where inorganic iodine levels are low, endemic goiter (enlarged thyroid) can arise in response to the need to maintain levels of thyroid hormone. In such circumstances, thyroid toxins such as glucosinolates can exacerbate problems with thyroid function. Deficiencies in thyroid function can result in retarded sexual maturation and mental retardation in low-iodine regions (typically, remote areas far from the sea).

Past work has suggested that evolution of the TAS2R family of bitter taste receptors has been shaped by the potential advantage of avoiding certain toxic compounds in plants, but the evidence thus far has been based on findings that used synthetic bitter compounds. For example, past work showed that people possessing genetically different versions of a particular TAS2R receptor exhibit correspondingly different sensitivities to the bitter compounds phenylthiocarbamide (PTC) and propylthiouracil (PROP), which resemble glucosinolates.

In the new work, researchers were able to show that different genetic versions of this same receptor, known as hTAS2R38, specifically determine people's perception of plants that synthesize glucosinolates
'"/>

Contact: Heidi Hardman
hhardman@cell.com
617-397-2879
Cell Press
18-Sep-2006


Page: 1 2

Related biology news :

1. Dont overlook urban soil
2. Dont move a muscle: Evolutionary insight into myogenesis
3. Dont hold your breath: Carp can manage without oxygen for months
4. Genes in Uniform: Dont Test, Dont Tell
5. Dont count on vitamin C to boost your exercise performance
6. Dont stand so close to me: A new view on how species coexist
7. Cell receptor may lead to new biomarker for pancreatic cancer
8. Menthol receptor also important in detecting cold temperatures
9. Systems characterization of cell surface receptors
10. OHSU lab finds meth receptor that could lead to therapy
11. Joslin study indicates insulin receptors play a critical role in promoting islet growth

Post Your Comments:
(Date:2/24/2015)... DUBLIN , Feb. 24, 2015 Research ... announced the addition of the "Global 2D ... offering. The analysts forecast the ... a CAGR of 32.12% over the period 2014-2019 ... devices in non-traditional sectors is one of the ...
(Date:2/13/2015)... -- ACT Genomics Co., Ltd., a cancer molecular ... genomic information into precision diagnosis and personalized treatments, ... million in the its first private funding round. ... , ACT Genomics has developed comprehensive cancer ... implement next generation sequencing (NGS) and multiplex molecular ...
(Date:2/10/2015)... 10, 2015  Alere Inc. (NYSE: ALR), a ... results for the quarter ended December 31, 2014. ... President of Alere said, "We made substantial progress ... the global leader in rapid diagnostics and delivering ... Health divestiture in early January enabled us to ...
Breaking Biology News(10 mins):Global 2D Gesture Recognition Market 2015-2019 with Cognitec Systems, CogniVue, eyeSight Mobile Technologies & PointGrab Dominating 2ACT Genomics Raises $8 Million in its First Private Funding Round 2Alere Inc. Announces Fourth Quarter 2014 Results 2Alere Inc. Announces Fourth Quarter 2014 Results 3Alere Inc. Announces Fourth Quarter 2014 Results 4Alere Inc. Announces Fourth Quarter 2014 Results 5Alere Inc. Announces Fourth Quarter 2014 Results 6Alere Inc. Announces Fourth Quarter 2014 Results 7Alere Inc. Announces Fourth Quarter 2014 Results 8Alere Inc. Announces Fourth Quarter 2014 Results 9Alere Inc. Announces Fourth Quarter 2014 Results 10Alere Inc. Announces Fourth Quarter 2014 Results 11Alere Inc. Announces Fourth Quarter 2014 Results 12Alere Inc. Announces Fourth Quarter 2014 Results 13Alere Inc. Announces Fourth Quarter 2014 Results 14Alere Inc. Announces Fourth Quarter 2014 Results 15Alere Inc. Announces Fourth Quarter 2014 Results 16Alere Inc. Announces Fourth Quarter 2014 Results 17Alere Inc. Announces Fourth Quarter 2014 Results 18Alere Inc. Announces Fourth Quarter 2014 Results 19Alere Inc. Announces Fourth Quarter 2014 Results 20Alere Inc. Announces Fourth Quarter 2014 Results 21Alere Inc. Announces Fourth Quarter 2014 Results 22Alere Inc. Announces Fourth Quarter 2014 Results 23Alere Inc. Announces Fourth Quarter 2014 Results 24Alere Inc. Announces Fourth Quarter 2014 Results 25Alere Inc. Announces Fourth Quarter 2014 Results 26Alere Inc. Announces Fourth Quarter 2014 Results 27Alere Inc. Announces Fourth Quarter 2014 Results 28Alere Inc. Announces Fourth Quarter 2014 Results 29Alere Inc. Announces Fourth Quarter 2014 Results 30Alere Inc. Announces Fourth Quarter 2014 Results 31Alere Inc. Announces Fourth Quarter 2014 Results 32Alere Inc. Announces Fourth Quarter 2014 Results 33Alere Inc. Announces Fourth Quarter 2014 Results 34
(Date:2/27/2015)... 2015 A paper published today, " ... " in Science Translational Medicine, demonstrates ... reduce the risk associated with investing in the ... levels of funding for developing so-called "orphan" drugs. ... collaboration between scientists at the National Center for ...
(Date:2/27/2015)... (PRWEB) February 27, 2015 Immunovaccine ... and immunotherapy company, today announced that the U.S. ... for Fast Track designation and Phase I clinical ... conjunction with the mutual co-development agreement signed with ... Fast Track designation for the DPX-Survivac. , “We ...
(Date:2/27/2015)... , Feb. 27, 2015 Bionomics Limited ... the DisrupTOR-1 trial of BNC105 in patients with metastatic ... Orlando, Florida . The data will ... the City of Hope Comprehensive Cancer Center in ... The new data identifies Ferritin and IL-8 ...
(Date:2/27/2015)... 2015 FamilyFarms Group is pleased to ... State Line Farms, received the 2015 Tomorrow’s Top Producer ... the age of 35, who has demonstrated excellence in ... to win the Tomorrow's Top Producer Horizon Award. Every ... Top Producer Award and learning from their experiences. It ...
Breaking Biology Technology:New Financing Technique May Hold Key to Unlocking Funding for Rare Diseases 2New Financing Technique May Hold Key to Unlocking Funding for Rare Diseases 3New Financing Technique May Hold Key to Unlocking Funding for Rare Diseases 4Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 2Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 3New BNC105 Biomarker Data to be Presented at US Cancer Conference 2New BNC105 Biomarker Data to be Presented at US Cancer Conference 3New BNC105 Biomarker Data to be Presented at US Cancer Conference 4New BNC105 Biomarker Data to be Presented at US Cancer Conference 5Matt Sims Receives the 2015 Tomorrow’s Top Producer Horizon Award 2
Cached News: